Min Grant, MD
Neurology · Indianapolis, INNPI 1679133698
Payments from drug & device makers
Across 56 payments — averaging $32.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Vanda Pharmaceuticals Inc.$554
- Argenx US, Inc.$143
- Harmony Biosciences LLC$131
- E.r. Squibb & Sons, L.L.C.$123
- Novartis$104
- AstraZeneca$85
- plus $669 from 16 others
What the payments were for
- Food & beverage$1,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $554 |
| Argenx US, Inc. | 5 | $143 |
| Harmony Biosciences LLC | 6 | $131 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Novartis | 5 | $104 |
| AstraZeneca | 3 | $85 |
| Lundbeck LLC | 3 | $79 |
| TG Therapeutics, Inc. | 3 | $77 |
| Octapharma USA, Inc. | 2 | $59 |
| Tanabe Pharma America, Inc. | 3 | $57 |
| Amgen | 3 | $51 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $51 |
| Springworks Therapeutics, Inc. | 2 | $42 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Eisai Inc. | 2 | $28 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| AbbVie | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,808 in reported general payments places this provider in the 45th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 15 | $128,650 |
| TecfideraDimethyl Fumarate | 11 | $104,528 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $101,868 |
| FingolimodFingolimod Hcl | 14 | $37,986 |
| Teriflunomide | 14 | $12,907 |
| Dimethyl Fumarate | 12 | $1,657 |
| Baclofen | 52 | $1,188 |
| AmantadineAmantadine Hcl | 12 | $966 |
| Duloxetine Hcl | 24 | $777 |
| Dalfampridine ErDalfampridine | 11 | $623 |
| MethotrexateMethotrexate Sodium | 15 | $606 |
| Gabapentin | 29 | $373 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $242 |
| Tizanidine Hcl | 16 | $163 |
| Amitriptyline Hcl | 20 | $154 |
Paid to pharmacies, not to this prescriber.
Other neurology in Indianapolis
- Kristi GeorgeIndianapolis$10.8M
- Craig HerrmanIndianapolis$7.8M
- Martin FarlowIndianapolis$4.8M
- Jared BroschIndianapolis$4.7M
- Alexandru BarboiIndianapolis$1.9M
- Kathryn NevelIndianapolis$1M
- Liana ApostolovaIndianapolis$990K
- Robert PascuzziIndianapolis$582K
- Adam ComerIndianapolis$382K
- Cynthia BodkinIndianapolis$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.